Therapeutic targets for neurodegenerative conditions are constantly emerging. Diseases such as amyotrophic lateral sclerosis and Huntington×³s disease are multifactorial and involve dysfunction of various cellular pathways. Protein aggregate formation is one of the crucial pathological signs of cellular dysfunction, and is characteristic of many neurodegenerative conditions. Proteins recruited to these aggregates are thought to play a role in formation of the pathogenic inclusions. This review aims at exploring the current evidence for protein aggregation and the role for Arfaptin2, as a candidate factor contributing to the formation of aggresomes and a potential therapeutic target in motor neuron disease.
Understanding the multifactorial nature of the pathogenesis of neurodegenerative diseases will contribute to the research into the therapeutic targets of the disease, allowing more factors to be discovered in patients affected by the debilitating disorders of the nervous system.
Collaborative efforts in investigating the causes and pathways of neurodegeneration are likely to increase the chance of discovering novel therapy approaches that may be utilised in more than one type of neurodegenerative disorders.
The application of the novel therapeutic target such as Arfaptin, and other proteins associated with protein aggregates, to the development of therapy approaches may open new avenues in drug discovery for neurodegenerative diseases.
Diseases of central nervous system bear a great impact on the quality of life of the patients and their carers. Promoting the awareness through communicating the current state of the research provides a form of a mental support to those affected by these conditions.
The need for funding the research into the basic understanding of the mechanisms involved in the pathogenesis of the neurodegenerative conditions must not be overlooked. The research into the cellular defects provides with invaluable findings about the healthy and diseased cell functioning.
Amyotrophic lateral sclerosisArfaptin2Huntington×³s diseaseMotor neuron diseaseNeurodegenerative diseaseProtein aggregationProtein degradationTherapeutic target
Gamma-Secretase Inhibitor (DAPT), a potential therapeutic target drug, caused neurotoxicity in planarian regeneration by inhibiting Notch signaling pathway.
Dong Z, Huo J, Liang A, Chen J, Chen G, Liu D
The Science of the total environment. 2021; 781(): 146735
Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma.
Fischietti M, Eckerdt F, Blyth GT, Arslan AD, Mati WM, Oku CV, Perez RE, Lee-Chang C, Kosciuczuk EM, Saleiro D, Beauchamp EM, Lesniak MS, Verzella D, Sun L, Fish EN, Yang GY, Qiang W, Platanias LC
Oncogene. 2021; ():
Nerve transfer for restoration of lower motor neuron-lesioned bladder function. Part 2: Attenuation of purinergic bladder smooth muscle contractions.
Frara N, Giaddui D, Braverman AS, Porreca DS, Brown JM, Mazzei M, Wagner IJ, Pontari MA, Tiwari E, Testa CL, Yu D, Hobson LJ, Barbe MF, Ruggieri MR
American journal of physiology. Regulatory, integrative and comparative physiology. 2021; ():
Effects of a bacteria-produced algicide on non-target marine invertebrate species.
Simons VE, Coyne KJ, Warner ME, Dolan MM, Cohen JH
Scientific reports. 2021; 11(1): 583
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.
Spivak JL, Moliterno AR
Frontiers in oncology. 2021; 11(): 641613
Potential compounds from several Indonesian plants to prevent SARS-CoV-2 infection: A mini-review of SARS-CoV-2 therapeutic targets.
Illian DN, Siregar ES, Sumaiyah S, Utomo AR, Nuryawan A, Basyuni M
Heliyon. 2021; 7(1): e06001
A "Target Class" Screen to Identify Activators of Two-Pore Domain Potassium (K2P) Channels.
McCoull D, Ococks E, Large JM, Tickle DC, Mathie A, Jerman J, Wright PD
SLAS discovery : advancing life sciences R & D. 2021; 26(3): 428-438
A fusion transcription factor-driven cancer progresses to a fusion-independent relapse via constitutive activation of a downstream transcriptional target.
Boudjadi S, Pandey PR, Chatterjee B, Nguyen TH, Sun W, Barr FG
Cancer research. 2021; ():